Distinct neuroinflammatory signatures exist across genetic and sporadic amyotrophic lateral sclerosis cohorts
Brain · 2023
DOI: 10.1093/brain/awad243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2023. Verfasst von Olivia M Rifai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Translational Neuroscience PhD Programme, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Frontotemporal Dementia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NINDS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of upper and lower motor neurons. ALS is on a pathogenetic disease spectrum with frontotemporal dementia, referred to as ALS-frontotemporal spectrum disorder (ALS-FTSD). For mutations associated with ALS-FTSD, such as the C9orf72 hexanucleotide repeat expansion, the molecular factors associated with heterogeneity along this spectrum require further characterization. Here, using a targeted NanoString molecular barcoding approach, we interrogate neuroinflammatory dysregulation and heterogeneity at the level of gene expression in post-mortem motor cortex tissue from a cohort of clinically heterogeneous C9-ALS-FTSD cases. We identified 20 dysregulated genes in C9-ALS-FTSD, with enrichment of microglial and inflammatory response gene sets. Two genes with significant correlations to available clinical metrics were selected for validation: FKBP5, a correlate of cognitive function, and brain-derived neurotrophic factor (BDNF), a correlate of disease duration. FKBP5 and its signalling partner, NF-κB, appeared to have a cell type-specific staining distribution, with activated (i.e. nuclear) NF-κB immunoreactivity in C9-ALS-FTSD. Expression of BDNF, a correlate of disease duration, was confirmed to be higher in individuals with long compared to short disease duration using BaseScope™ in situ hybridization. Our analyses also revealed two distinct neuroinflammatory panel signatures (NPS), NPS1 and NPS2, delineated by the direction of expression of proinflammatory, axonal transport and synaptic signalling pathways. We compared NPS between C9-ALS-FTSD cases and those from sporadic ALS and SOD1-ALS cohorts and identified NPS1 and NPS2 across all cohorts. Moreover, a subset of NPS was also able to separate publicly available RNA sequencing data from independent C9-ALS and sporadic ALS cohorts into two inflammatory subgroups. Importantly, NPS subgroups did not clearly segregate with available demographic, genetic, clinical or pathological features, highlighting the value of molecular stratification in clinical trials for inflammatory subgroup identification. Our findings thus underscore the importance of tailoring therapeutic approaches based on distinct molecular signatures that exist between and within ALS-FTSD cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Neuroscience PhD Programme, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK.
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB, UK.
- UK Dementia Research Institute, University of Edinburgh, Edinburgh, EH16 4SB, UK.
- Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, EH16 4SB, UK.
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK.
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, EH8 9XF, UK.
ORCID-Profile: Olivia M Rifai, Owen R Dando, Michael D E Sewell
Förderung
- Wellcome Trust
- NINDS NIH HHS
- NIH HHS
- Pathological Society and Jean Shanks Foundation
- NIH
- Motor Neuron Disease
- Sir Henry Dale Fellowship
- Royal Society
Zitieren
APA
Rifai, O. M., O'Shaughnessy, J., Dando, O. R., Munro, A. F., Sewell, M. D. E., Abrahams, S., Waldron, F. M., Sibley, C. R., & Gregory, J. M. (2023). Distinct neuroinflammatory signatures exist across genetic and sporadic amyotrophic lateral sclerosis cohorts. Brain. https://doi.org/10.1093/brain/awad243
Vancouver
Rifai OM, O'Shaughnessy J, Dando OR, Munro AF, Sewell MDE, Abrahams S, et al. Distinct neuroinflammatory signatures exist across genetic and sporadic amyotrophic lateral sclerosis cohorts. Brain. 2023. doi:10.1093/brain/awad243
BibTeX
@article{Rifai2023,
author = {Rifai, Olivia M and O'Shaughnessy, Judi and Dando, Owen R and Munro, Alison F and Sewell, Michael D E and Abrahams, Sharon and Waldron, Fergal M and Sibley, Christopher R and Gregory, Jenna M},
title = {Distinct neuroinflammatory signatures exist across genetic and sporadic amyotrophic lateral sclerosis cohorts},
journal = {Brain},
year = {2023},
doi = {10.1093/brain/awad243}
}
EUVIMED